N-substituted azaindoles as potent inhibitors of Cdc7 kinase

被引：30

作者：

Bryan, Marian C. ^{[1
]}

Falsey, James R. ^{[1
]}

Frohn, Mike ^{[2
]}

Reichelt, Andreas ^{[2
]}

Yao, Guomin ^{[2
]}

Bartberger, Michael D. ^{[2
]}

Bailis, Julie M. ^{[3
]}

Zalameda, Leeanne ^{[4
]}

San Miguel, Tisha ^{[4
]}

Doherty, Elizabeth M. ^{[1
]}

Allen, John G. ^{[2
]}

机构：

[1] Amgen Inc, Therapeut Discovery, Med Chem Res Technol, Thousand Oaks, CA 91320 USA

[2] Amgen Inc, Therapeut Discovery, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA

[3] Amgen Inc, Oncol Res, San Francisco, CA 94080 USA

[4] Amgen Inc, Therapeut Discovery, Bioassay & Profiling, Thousand Oaks, CA 91320 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2013年 / 23卷 / 07期

关键词：

Cdc7; inhibitors; Azaindole; Cell division cycle; Conformational analysis; CELL-DIVISION CYCLE; DNA-REPLICATION; CANCER-THERAPY; CHECKPOINT; PYRROLOPYRIDINONES; INITIATION; DISCOVERY; LINES;

D O I：

10.1016/j.bmcl.2013.02.007

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Cdc7 kinase is responsible for the initiation and regulation of DNA replication and has been proposed as a target for cancer therapy. We have identified a class of Cdc7 inhibitors based on a substituted indole core. Synthesis of focused indole and azaindole analogs yielded potent and selective 5-azaindole Cdc7 inhibitors with improved intrinsic metabolic stability (ie 36). In parallel, quantum mechanical conformational analysis helped to rationalize SAR observations, led to a proposal of the preferred binding conformation in the absence of co-crystallography data, and allowed the design of 7-azaindole 37 as a second lead in this series. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：2056 / 2060

页数：5

共 24 条

[11] Cdc7 Kinase Inhibitors: 5-Heteroaryl-3-Carboxamido-2-Aryl Pyrroles as Potential Antitumor Agents. 1. Lead Finding [J].

Menichincheri, Maria ;

Albanese, Clara ;

Alli, Cristina ;

Ballinari, Dario ;

Bargiotti, Alberto ;

Caldarelli, Marina ;

Ciavolella, Antonella ;

Cirla, Alessandra ;

Colombo, Maristella ;

Colotta, Francesco ;

Croci, Valter ;

D'Alessio, Roberto ;

D'Anello, Matteo ;

Ermoti, Antonella ;

Fiorentini, Francesco ;

Forte, Barbara ;

Galvani, Arturo ;

Giordano, Patrizia ;

Isacchi, Antonella ;

Martina, Katia ;

Molinari, Antonio ;

Moll, Juegen K. ;

Montagnoli, Alessia ;

Orsini, Paolo ;

Orzi, Fabrizio ;

Pesenti, Enrico ;

Pillan, Antonio ;

Roletto, Fulvia ;

Scolaro, Alessandra ;

Tato, Marco ;

Tibolla, Marcellino ;

Valsasina, Barbara ;

Varasi, Mario ;

Vianello, Paola ;

Volpi, Daniele ;

Santocanale, Corrado ;

Vanottit, Ermes .

JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (20) :7296-7315

[12] First Cdc7 Kinase Inhibitors: Pyrrolopyridinones as Potent and Orally Active Antitumor Agents. 2. Lead Discovery [J].

Menichincheri, Maria ;

Bargiotti, Alberto ;

Berthelsen, Jens ;

Bertrand, Jay A. ;

Bossi, Roberto ;

Ciavolella, Antonella ;

Cirla, Alessandra ;

Cristiani, Cinzia ;

Croci, Valter ;

D'Alessio, Roberto ;

Fasolini, Marina ;

Fiorentini, Francesco ;

Forte, Barbara ;

Isacchi, Antonella ;

Martina, Katia ;

Molinari, Antonio ;

Montagnoli, Alessia ;

Orsini, Paolo ;

Orzi, Fabrizio ;

Pesenti, Enrico ;

Pezzetta, Daniele ;

Pillan, Antonio ;

Poggesi, Italo ;

Roletto, Fulvia ;

Scolaro, Alessandra ;

Tato, Marco ;

Tibolla, Marcellino ;

Valsasina, Barbara ;

Varasi, Mario ;

Volpi, Daniele ;

Santocanale, Corrado ;

Vanotti, Ermes .

JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (02) :293-307

[13] Cdc7 inhibition reveals a p53-dependent replication checkpoint that is defective in cancer cells [J].

Montagnoli, A ;

Tenca, P ;

Sola, F ;

Carpani, D ;

Brotherton, D ;

Albanese, C ;

Santocanale, C .

CANCER RESEARCH, 2004, 64 (19) :7110-7116

[14] A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity [J].

Montagnoli, Alessia ;

Valsasina, Barbara ;

Croci, Valter ;

Menichincheri, Maria ;

Rainoldi, Sonia ;

Marchesi, Vanessa ;

Tibolla, Marcello ;

Tenca, Pierluigi ;

Brotherton, Deborah ;

Albanese, Clara ;

Patton, Veronica ;

Alzani, Rachele ;

Ciavolella, Antonella ;

Sola, Francesco ;

Molinari, Antonio ;

Volpi, Daniele ;

Avanzi, Nilla ;

Fiorentini, Francesco ;

Cattoni, Marina ;

Healy, Sandra ;

Ballinari, Dario ;

Pesenti, Enrico ;

Isacchi, Antonella ;

Moll, Jurgen ;

Bensimon, Aaron ;

Vanotti, Ermes ;

Santocanale, Corrado .

NATURE CHEMICAL BIOLOGY, 2008, 4 (06) :357-365

[15] Targeting Cell Division Cycle 7 Kinase: A New Approach for Cancer Therapy [J].

Montagnoli, Alessia ;

Moll, Juergen ;

Colotta, Francesco .

CLINICAL CANCER RESEARCH, 2010, 16 (18) :4503-4508

[16] Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability [J].

Nassar, AEF ;

Kamel, AM ;

Clarimont, C .

DRUG DISCOVERY TODAY, 2004, 9 (23) :1020-1028

[17]

Reichelt A., EUR J MED CHEM UNPUB

[18] Targeting DNA Replication before it Starts Cdc7 as a Therapeutic Target in p53-Mutant Breast Cancers [J].

Rodriguez-Acebes, Sara ;

Proctor, Ian ;

Loddo, Marco ;

Wollenschlaeger, Alex ;

Rashid, Mohammed ;

Falzon, Mary ;

Prevost, A. Toby ;

Sainsbury, Richard ;

Stoeber, Kai ;

Williams, Gareth H. .

AMERICAN JOURNAL OF PATHOLOGY, 2010, 177 (04) :2034-2045

[19]

Sawa M., 2008, DRUG DES DEV THER, V2, P255

[20] 4-(1H-Indazol-5-yl)-6-phenylpyrimidin-2(1H)-one analogs as potent CDC7 inhibitors [J].

Shafer, Cynthia M. ;

Lindvall, Mika ;

Bellamacina, Cornelia ;

Gesner, Thomas G. ;

Yabannavar, Asha ;

Jia, Weiping ;

Lin, Song ;

Walter, Annette .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (16) :4482-4485

← 1 2 3 →